HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health, Beauty And Wellness News: POM Wonderful On 'Health Scare' Swim In Ad

This article was originally published in The Rose Sheet

Executive Summary

Online, pamphlet claims trip Baker's Best; MusclePharm maintains turnaround progress; Kameka enters probiotic market through AB-Biotics; and POM Wonderful ad swims on humor.

You may also be interested in...



MusclePharm Sheds 75% Of Portfolio, Flexes After Spending Stretched It Thin

MusclePharm whittled its product line from 450 to 120 SKUs  and is shifting its distribution focus in the US from specialty retail to Amazon and Costco. The firm also cut operating costs, spending $10m less in 2017 than in 2016.

Supreme Court Slays POM Wonderful's Appeal Of FTC Order

The high court denies the firm's writ of certiorari to review an appellate 2015 ruling largely upholding a 2013 FTC order on claims made for POM Wonderful 100% Pomegranate Juice and POMx pills and liquid supplements.

Outlook 2023: Market Experts On Importance Of Value, Mental Health In A ‘World On Fire’

Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121620

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel